Your browser is no longer supported. Please, upgrade your browser.
Navidea Biopharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.45 Insider Own0.40% Shs Outstand28.07M Perf Week-1.52%
Market Cap57.21M Forward P/E- EPS next Y-0.40 Insider Trans78.20% Shs Float20.70M Perf Month20.37%
Income-11.70M PEG- EPS next Q-0.08 Inst Own6.50% Short Float0.87% Perf Quarter-6.25%
Sales0.90M P/S63.57 EPS this Y37.30% Inst Trans17.93% Short Ratio0.96 Perf Half Y-8.02%
Book/sh0.15 P/B13.00 EPS next Y-33.30% ROA-151.00% Target Price- Perf Year-52.21%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.46 - 5.36 Perf YTD-9.30%
Dividend- P/FCF- EPS past 5Y33.80% ROI-535.60% 52W High-63.97% Beta1.72
Dividend %- Quick Ratio2.10 Sales past 5Y-41.40% Gross Margin100.00% 52W Low32.20% ATR0.14
Employees13 Current Ratio2.10 Sales Q/Q-50.00% Oper. Margin- RSI (14)54.78 Volatility11.49% 7.10%
OptionableYes Debt/Eq0.05 EPS Q/Q20.10% Profit Margin- Rel Volume0.03 Prev Close1.95
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume189.47K Price1.93
Recom2.00 SMA202.47% SMA5011.03% SMA200-12.83% Volume453 Change-1.02%
Nov-13-13Reiterated Aegis Capital Hold $3 → $2
Nov-07-13Reiterated Ladenburg Thalmann Buy $7.50 → $3
Jan-24-13Initiated Burrill Institutional Research Mkt Outperform $5
Jan-22-13Initiated Aegis Capital Hold $3
Sep-11-12Reiterated WBB Securities Strong Buy $9 → $7
Sep-11-12Reiterated Rodman & Renshaw Mkt Outperform $7 → $6
Sep-11-12Reiterated Ladenburg Thalmann Buy $6.25 → $7.50
Jun-24-21 07:00AM  
Jun-14-21 07:32PM  
May-19-21 07:30AM  
May-11-21 04:01PM  
May-05-21 08:00AM  
May-04-21 07:30AM  
Apr-15-21 07:30AM  
Mar-24-21 04:21PM  
Mar-17-21 07:30AM  
Mar-02-21 04:01PM  
Feb-09-21 08:09AM  
Feb-08-21 04:05PM  
Jan-07-21 07:30AM  
Dec-28-20 07:30AM  
Dec-08-20 09:51AM  
Nov-26-20 06:34PM  
Nov-12-20 04:02PM  
Nov-05-20 04:01PM  
Oct-29-20 12:35PM  
Oct-22-20 07:30AM  
Oct-09-20 07:30AM  
Sep-28-20 07:30AM  
Sep-08-20 04:05PM  
Sep-02-20 04:05PM  
Aug-31-20 05:00PM  
Aug-24-20 04:05PM  
Aug-13-20 04:09PM  
Aug-10-20 09:08AM  
Aug-06-20 04:15PM  
Aug-05-20 07:30AM  
Jun-25-20 03:50AM  
Jun-17-20 09:43AM  
Jun-15-20 08:00AM  
Jun-09-20 07:30AM  
Jun-03-20 07:30AM  
May-26-20 10:11AM  
May-22-20 08:35AM  
May-21-20 04:30PM  
May-14-20 04:01PM  
May-11-20 07:30AM  
May-07-20 07:00AM  
Apr-22-20 07:30AM  
Apr-21-20 08:52AM  
Mar-31-20 07:30AM  
Mar-24-20 04:19PM  
Mar-20-20 07:00AM  
Mar-11-20 04:05PM  
Mar-04-20 08:00AM  
Feb-21-20 08:42AM  
Feb-14-20 11:56AM  
Feb-12-20 09:20AM  
Dec-30-19 05:19PM  
Dec-14-19 09:41AM  
Dec-06-19 06:23PM  
Dec-05-19 03:45PM  
Dec-02-19 02:08PM  
Nov-19-19 10:41PM  
Nov-14-19 08:30AM  
Nov-13-19 07:38AM  
Nov-07-19 04:05PM  
Oct-31-19 07:30AM  
Oct-29-19 07:30AM  
Oct-14-19 03:42PM  
Sep-06-19 04:05PM  
Aug-27-19 07:30AM  
Aug-08-19 04:05PM  
Aug-01-19 04:05PM  
Jun-24-19 07:46AM  
Jun-18-19 04:05PM  
Jun-17-19 05:16PM  
Jun-13-19 11:16PM  
May-08-19 06:28PM  
May-01-19 04:05PM  
Apr-26-19 07:30AM  
Apr-19-19 04:05PM  
Apr-08-19 07:30AM  
Apr-02-19 04:05PM  
Mar-22-19 05:08PM  
Mar-13-19 01:31PM  
Mar-07-19 04:05PM  
Feb-28-19 07:00AM  
Feb-01-19 07:00AM  
Jan-24-19 07:00AM  
Dec-07-18 06:55AM  
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694 and NAV5001, a neuro-tracer product candidates. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Witter Malcolm GDirectorApr 23Buy1.6010,00016,00057,000Apr 26 05:14 PM
Witter Malcolm GDirectorMar 29Buy2.0721,50044,50547,000Mar 29 04:38 PM
Witter Malcolm GDirectorMar 03Buy2.3115,00034,65025,500Mar 03 04:34 PM
Witter Malcolm GDirectorDec 28Buy2.075,00010,35010,500Dec 30 04:33 PM
Scott John K Jr.10% OwnerAug 30Buy5.005,00025,0008,047,162Sep 02 09:47 PM